After a $28 million financing, Provention Bio has grabbed two IBD candidates from Janssen that should make it a double clinical-stage biotech in 2018.

VC Lightstone has $250 million in the bank for life science research.

Iontas will use its phage display libraries and other antibody discovery capabilities to provide Glythera with a key component of its planned ADCs.

Arcus has signed a deal with Taiho that provides a healthy cash injection while keeping rights in the U.S. and other markets in hand.

The clean sweep is a big win for Alnylam and the Sanofi-partnered RNAi drug, which is now set to be put before regulators at the end of the year.

Eric Carlson, Ph.D., has become the latest in a string of former Alcon employees to land at the smaller eye disease specialist.

Acceleron's collaboration with Celgene on sotatercept has taken another turn, giving Acceleron the right to develop the drug for pulmonary diseases.

Disarm Therapeutics has seen a strong $30 million series A round as it looks for a breakthrough approach in axonal degeneration.

Ultragenyx is putting up $138 million in cash to wrestle gene therapy biotech Dimension away from its first suitor.

R&D